Answers are grounded in this paper and cite their sources.
Background and aims Alcohol-related hepatitis (AH) and alcohol-related cirrhosis are grave conditions with poor prognoses. Altered hepatic lipid metabolism can impact disease development and varies between different alcohol-related liver diseases. Therefore, we aimed to investigate lipidomics and metabolomics at various stages of alcohol-related liver diseases and their correlation with survival. Methods Patients with newly diagnosed alcohol-related cirrhosis, who currently used alcohol (ALC-A), stable outpatients with decompensated alcohol-related cirrhosis with at least eight weeks of alcohol abstinence (ALC), and patients with AH, were compared to each other and to healthy individuals (HC). Circulating lipids and metabolites were analysed using high-performance liquid chromatography and mass spectrometry. Results 40 patients with ALC, 95 with ALC-A, 30 with AH, and 42 HC provided plasma. Lipid levels changed according to disease severity, with generally lower levels in AH and cirrhosis than in the healthy control group; this was most pronounced for AH, followed by ALC-A. Nine out of ten free fatty acids differed between cirrhosis groups by relative increases of 0.12–0.66 in ALC compared to the ALC-A group ( p -values <0.0005). For metabolomics, total bile acids increased by 19.7, 31.3 and 80.4 in the ALC, ALC-A and AH group, respectively, compared to HC (all p -values <0.0001). Low sphingolipid ((d42:1) and (d41:1)) levels could not predict 180-day mortality (AUC=0.73, p =0.95 and AUC=0.73, p =0.95) more accurate than the MELD score (AUC=0.71), but did predict 90-day mortality (AUC d42:1 =0.922, AUC d41:1 =0.893; p d42:1 =0.005, p d41:1 =0.007) more accurately than the MELD score AUC MELD =0.70, p MELD =0.19). Conclusions Alcohol-related severe liver disease is characterized by low lipid levels progressing with severity of liver disease, especially low sphingomyelins, which also associate to poor prognoses. Clinical trial number H-21013476. Impact and implication Lipidomics has the potential to diagnose and risk stratificate patients with liver diseases. Lipidomics differed between patients with alcohol-related hepatitis and alcohol-related cirrhosis with and without recent alcohol use. Furthermore, lipidomics could predict short-term mortality and might be suitable as a prognostic tool in the future.
No takes yet. Share an insight, caveat, or question.
Kronborg et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: